医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Wipro Cited as a Leader in Worldwide Life Science Manufacturing and Supply Chain ITO by Independent Research Firm

2014年01月23日 PM11:25
このエントリーをはてなブックマークに追加


 

BANGALORE, India & EAST BRUNSWICK, New Jersey

Wipro Ltd. (NYSE:WIT), a leading global information technology, consulting and outsourcing company has been named ‘Leader’ by technology global research and advisory firm International Data Corporation (IDC) in its report IDC MarketScape: Worldwide Life Science Manufacturing and Supply Chain ITO 2013 Vendor Assessment, Doc #HI244265, November 2013.

IDC evaluated leading Life Science Manufacturing and Supply Chain ITO Services providers across 24 criteria relating to current offering, strategy and market presence based on client inquiries, user needs assessments, and vendor and expert interviews. It identified Wipro as a leader in Worldwide Life Science Manufacturing and Supply Chain ITO.

Elaborating on Wipro’s experience with Life Sciences clients, the report states that “Wipro has extensive experience working with medical device companies, complemented by mid-level experience with pharmaceutical and biotech companies as well. The vast majority of Wipro’s life science customers are large corporations with revenues of over $1 billion, with a smaller portion spread across midsize and small firms. While more than half of its client base is North American based, it does have a significant client base across all regions of the world, including Europe, Asia, and Latin America, with multiple delivery centers in each region as well.”

IDC has rated Wipro highly for client centricity based on customer interviews conducted across all the vendors. The report further states “Relative to other vendors discussed in this report, and based on feedback from multiple customer references, Wipro scored the highest among all vendors for account management capabilities and received high marks for technical skills and overall level of value delivered to its clients.”

Elaborating on Wipro’s vision and focus, Nitin Raizada – Global Practice Head – Industry Solutions Group, Life Sciences, Wipro, said “We continue to consolidate our position and strengthen our performance. I believe this increase in momentum is the result of a set of structured things we are doing to drive ‘sustainable’ and ‘predictable’ growth. Our continued focus on patient centricity, compliance and commercial effectiveness is showing results. We have gained traction in winning large transformation and domain specific deals by pursuing Wipro’s three-pronged strategy of programmatic mining of existing accounts, new logo pursuits and creating differentiated domain offerings to solve real problems faced by clients.”

About Wipro Ltd.
Wipro Ltd. (NYSE:WIT) is a leading Information Technology, Consulting and Outsourcing company that delivers solutions to enable its clients do business better. Wipro delivers winning business outcomes through its deep industry experience and a 360 degree view of “Business through Technology” – helping clients create successful and adaptive businesses. A company recognized globally for its comprehensive portfolio of services, a practitioner’s approach to delivering innovation, and an organization wide commitment to sustainability, Wipro has a workforce of 140,000 serving clients across 61 countries. For more information, please visit www.wipro.com.

About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of IT, telecommunications, or industry-specific suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT, telecommunications, or industry-specific vendors can be meaningfully compared. The framework also provides technology buyers with a transparent foundation to allow companies to independently compare the strengths and weaknesses of current and prospective vendors.

Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

CONTACT

Wipro Ltd.
Purnima Burman
purnima.burman@wipro.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表